Managing hyponatraemia in a patient with malignant melanoma: a case report by Davies, Siwan H et al.
Case report
Open Access
Managing hyponatraemia in a patient with malignant melanoma:
a case report
Siwan H Davies
1, Margred M Capel
2* and Ilora Finlay
3
Addresses:
1St2, Core Medical Training, Velindre Hospital, Velindre Road, Whitchurch, Cardiff, CF14 2TL, UK
2The George Thomas Memorial Trust, Park Road, Whitchurch, Cardiff, CF14 7BQ, UK
3Velindre Hospital, Velindre Road, Whitchurch, Cardiff, CF14 2TL, UK
Email: SHD - siwanhaf@yahoo.com; MMC* - margred.capel@gthc.org.uk; IF - FINLAYI@parliament.uk
*Corresponding author
Received: 25 March 2009 Accepted: 24 June 2009 Published: 30 July 2009
Cases Journal 2009, 2:6899 doi: 10.4076/1757-1626-2-6899
This article is available from: http://casesjournal.com/casesjournal/article/view/6899
© 2009 Davies et al.; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
We report the case of a 46-year-old male with a known diagnosis of metastatic malignant melanoma
who presented with hyponatraemia. The report details the challenges we faced in identifying the
cause of his hyponatraemia and in attempting to reverse his electrolyte disturbance.
As his clinical condition deteriorated the focus of our management needed to change; recognising
that he was dying we implemented the Mental Capacity Act to make decisions in his best interest and
ensure he achieved a symptom controlled and dignified death.
Introduction
Hyponatraemia associated with malignancy is not
uncommon; the symptoms and management are well
documented [1]. However, the management of hypona-
traemia in a patient with metastatic melanoma and
adrenal metastases who has lost capacity to participate in
treatment decisions is more complex. Balancing the
aggressive management of his hyponatraemia against his
clinical condition, and adapting this for end-of-life care,
required tailoring the management to avoid burdening
him with investigations and treatments. Using the Mental
Capacity Act as a legal framework can aid decision making
in this case and in similar cases.
Case presentation
A 46-year-old Caucasian British male with metastatic
malignant melanoma was admitted to our palliative care
unit with worsening lethargy, generalized weakness,
profuse sweating, abdominal pain and constipation.
Medication on admission included dexamethasone, com-
menced seven months previously for tiredness and general
well being; the dose had recently been increased from
2 mg to 4 mg daily. Slow release morphine sulphate
90 mg 12 hourly and naproxen 500 mg b.d. for pain
control, and warfarin following a pulmonary embolism
and right iliac DVT diagnosed three months earlier. For
relief of constipation he had taken six sachets of Movicol
“
each day in the week prior to admission.
He had received his second cycle of carboplatin four weeks
prior to this admission. Recent CT scan confirmed disease
progression with tumour masses in the neck, superior
mediastinum, left flank and the adrenal glands bilaterally
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(page number not for citation purposes)(right 103 × 143 mm, left 122 × 164 mm). In addition,
numerous subcutaneous tumour nodules, nodular liver
metastases and significant retroperitoneal malignant
lymphadenopathy were noted. CT imaging of the brain
was unremarkable.
On examination he was euvolaemic without oedema.
There was a firm, large, tender mass in the left upper
quadrant. He was not confused and neurological exami-
nation was normal. There were numerous metastatic skin
deposits of varying size visible on his face and neck.
His blood count, liver function, thyroid function and
magnesium levels were all within normal reference ranges,
but on admission his sodium was 106 mmol/L and
potassium 5.9 mmol/L, urea 11.8 mmol/L and creatinine
104 mmol/L. Plasma osmolality was 242 mosmol/kg,
bicarbonate 19 mmol/L, glucose 4.6 mmol/L and random
cortisol 1 nmol/L. The initial urinary sodium was
79 mmol/L with a urinary osmolality of 596 mosmol/kg.
The blood results were surprisingly incongruous with the
patient’s physical and mental state on this admission.
The causes of hyponatraemia were considered with the
intention of correcting his electrolyte imbalance in order
to resolve his physical symptoms and restore his indepen-
dent and active lifestyle.
The combination of hyponatraemia and hyperkalaemia
with the evidence of significant bilateral adrenal tumours
and long-standing dexamethasone therapy led us to the
working diagnosis of hyponatraemia due to adrenal
insufficiency secondary to the adrenal metastases. His
electrolytes were documented within normal ranges two
weeks prior to this admission. Other aetiologies consid-
ered included that the two recent cycles of carboplatin
therapy had impaired his renal function leading to excess
sodium loss or reduced sodium reabsorption, or that
intense use of the osmotic laxative Movicol
“ may have
compounded his electrolyte imbalance.
The relevance of hyponatraemia as the underlying cause of
his physical symptoms was discussed at length with
the patient and his wife. Correction of his electrolyte
imbalance was agreed upon following advice from the
clinical biochemist.
Initial management strategies included commencing
fludrocortisone, restricting his fluid intake and disconti-
nuing his Movicol
“. Over the following days his sodium
remained between 105-108 mmol/L and his clinical
condition remained stable; whilst he was mostly con-
f i n e dt ob e da n dc h a i rh er e m a i n e dc o n s c i o u sw i t h o u t
seizures.
On day five of his admission he complained of sudden
onset left loin pain, much more severe than his usual
background pain, and became hypotensive and tachy-
cardic. It was hypothesized that he had haemorrhaged into
his adrenal tumour as his INR was 3.2 and Hb 9.7 g/dl
having fallen from 11.4 g/dl on admission. The patient
participated in discussions regarding his management and
declined a more aggressive approach including further
radiological investigations. He was commenced on a
continuous subcutaneous infusion of 100 mg diamor-
phine and 10 mg midazolam over 24 hours to manage his
pain. The dose was titrated against his background opioid
use and additional requirements. Ketamine was used for
additional analgesia and an opioid-sparing measure.
Hydrocortisone was prescribed in place of dexamethasone
and his warfarin was discontinued.
On day seven the patient was stable, his urinary sodium
had dropped from 79 mmol/L to 5 mmol/L but the
plasma sodium remained at 106 mmol/L. The plasma
sodium increased to 109 mmol/L by day nine and to 112
mmol/L bythe twelfth dayof admission. Unfortunately, as
the patient’s biochemistry improved his clinical condition
then deteriorated. He became confused, aggressive,
agitated and difficult to nurse.
Asthepatienthadbecomeunabletoparticipateindecision-
making, the Mental Capacity Act 2005 guidance - to
involve and consider information provided by people
whoarebestplacedtoexpressthepriorthoughtsandwishes
of the patient - was followed. Prior to this episode he had
discussed at length with his wife the extent to which he
wanted interventions and treatments, saying he
woulddeclinefurtherinvestigationsandtreatmentsinclud-
ing intravenous medication in the event of clinical
deterioration, fully understanding the implications of this
decision.
The clinical situation had evolved from admission. The
patient was entering his terminal phase for a combina-
tion of reasons. Pursuing resolution of his electrolyte
imbalance would no longer be in his best interests in this
context nor would it arrest the dying process. It would
c o n t r a d i c th i sw i s h e sa sr e p o r t e db yh i sw i f ea n dt h e
views he had expressed to the medical team when he was
capable of expressing his own autonomous informed
opinions.
Analgesia and sedation were continued via the syringe
driver and intravenous medication, including the hydro-
cortisone, ceased when peripheral access was lost. Central
access was not attempted in light of the patient’s prior
wishes. The patient died with his wife present fourteen
days after admission.
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The management of this patient presented us with
a number of challenges, both clinical and ethical with
some questions remaining unanswered. Hyponatraemia
may have accounted for the majority of his symptoms
(nausea, weakness, confusion in his last days), but on
admission he appeared surprisingly well and was not
confused despite his serum sodium of 106 mmol/L.
The interpretation and management of hyponatraemia is
complex and not based on plasma sodium alone.
Fundamental to its assessment is a measure of the patient’s
hydration status. Identification and correction of
the underlying cause is essential if the electrolyte
imbalance is to be reversed. In broad terms hyponatraemia
can be divided into hypovolaemic and eu/hypervolaemic
hyponatraemia, both types can be further subdivided
according to the urinary sodium concentration (less than
or more than 20 mmol/L). A thorough history of drug use,
fluid loss and examination of circulatory volume status
and measurement of urinary sodium concentration is
imperative in determining the cause and subsequently
devising an appropriate management strategy.
The aetiology of his hyponatraemia remained unproven
and was likely to be multifactorial. Several potential causes
were identified from the history. No consent to post-
mortem was obtained.
Nephrotoxic insults included both the NSAID he had used
in the weeks prior to admission and the recent cycles of
carboplatin. This may have contributed to excessive
sodium loss from the proximal tubule of the kidneys
and some failure of reabsorption. The NSAID was
discontinued on admission; the improvement in urea
and creatinine and subsequent improvement in plasma
sodium following the dramatic drop in urinary sodium
supports this hypothesis. The prolonged high volume
consumption of Movicol
“ may have contributed to his
hyponatraemia. There are published case-reports and data
from the Medicines Control Agency documenting hypo-
natraemia secondary to the use of osmotic laxatives such
as Movicol
“ [2].
A strong candidate for the cause of his hyponatraemia, and
our working diagnosis, on admission was adrenal insuffi-
ciency secondary to metastatic destruction of his adrenal
glands, suppression of his pituitary-adrenal axis following
long term treatment with dexamethasone and possibly
reduced dexamethasone absorption as a result of vomiting
and constipation. The random cortisol of 1 nmol/L
supports this theory although a Synacthen
“ test was not
performed following advice from our biochemist with
respect to meaningful interpretation. The patient was
prescribed adrenal replacement therapy initially with oral
dexamethasone (low mineralcorticoid activity) and fludro-
cortisone, respecting his preference for oral medication.
In practice it is likely that a combination of all these factors
contributed to his hyponatraemia, and the symptoms that
he experienced. The attempt to reverse his hyponatraemia
was undertaken on the principle of beneficence based on
his physical condition on admission being incongruous
with his electrolytes and extent of his metastatic disease. It
was his preference in light of his extensive disease to
remain on the inpatient unit and not transfer for the more
aggressive management within the hospital. He was fully
informed regarding the anticipated outcome of the
decisions he made to limit his treatment and investiga-
tions, yet he and his wife remained extremely grateful for
the effort and work performed by the team to try and
reverse his hyponatraemia and in communication, keep-
ing them informed and involved in decision making.
His treatment and investigations were limited by the place
of care; the complete reversal from 106 mmol/L was
always going to be a difficult challenge, and one that we
unfortunately failed to overcome on the inpatient
palliative care unit. Following treatment for 10 days with
little apparent improvement in his serum sodium con-
centration he became too unwell to be able to justify
ethically regular blood tests. It is possible that his sodium
continued to improve until death; on the other hand it
may have plummeted following cessation of hydro-
cortisone when intravenous access was lost and hastened
his demise. Application of the Mental Capacity Act
guidance enabled his wife to feel she continued to
participate in decision-making once the patient had lost
capacity and that the clinical team adhered to her
husband’s wishes as she perceived them.
There was considerable debate within the clinical team
regarding the management of this case particularly when
peripheral access was lost and central line placement was
potentially required. The debate included whether the
patient was dying with or as a consequence of his
hyponatraemia and the extent to which this should be
pursued. Following lengthy discussions, the whole team
were confident that the eventual management decisions
made were in the patient’s best interests as appraised by
these basic ethical values.
Conclusion
Adoption of an ethical framework in the management of
medical cases and maintaining an open dialogue with the
patient and their carers can facilitate decision making in
such complex cases. Palliative care works within the
confines of the healthcare system and the constraints of
individual patient’scircumstances, yet management can be
tailored to the individual, as this case illustrates.
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CT, computerized tomography; DVT, Deep vein throm-
bosis; NSAID, Non steroidal anti-inflammatory drug.
Consent
The patient described in this case-report has died and
attempts to locate his next of kin for consent for
publication have failed. However, all patient details have
been anonymised and we have no reason to believe that
the patient or their family would object to publication.
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